<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588077</url>
  </required_header>
  <id_info>
    <org_study_id>2020-24</org_study_id>
    <nct_id>NCT04588077</nct_id>
  </id_info>
  <brief_title>Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis</brief_title>
  <official_title>Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators want to compare the seroconversion rates between two-dose and three-dose&#xD;
      regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized&#xD;
      prospective study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Rationale:&#xD;
&#xD;
      Hepatitis B virus is a major cause of acute and chronic liver disease both in the United&#xD;
      States and worldwide. In 2016, an estimated 862,000 people were living with HBV infection in&#xD;
      the US with a total of 1,649 U.S. death certificates recorded as an underlying or&#xD;
      contributing cause of death. Chronic infection may cause liver cirrhosis and hepatocellular&#xD;
      carcinoma (HCC). Since the introduction of the vaccine in the 1990s, there has been a&#xD;
      significant decline in the incidence of HBV infection. Approved in November 2017, Heplisav-B&#xD;
      uses a synthetic cytosine phosphoguanine oligonucleotide derived from bacterial DNA; it is&#xD;
      thought to stimulate the immune system through activation of the toll-like receptor 9&#xD;
      pathway, which induces the production of cytokines such as interleukines such as&#xD;
      interleukine-12 and interferon-alpha. It has been shown to induce higher immunity in healthy&#xD;
      individuals compared to conventional vaccines.&#xD;
&#xD;
      The HBsAb titer should be checked 8 to 12 weeks after the administration of the vaccination&#xD;
      series. Good responders were defined as those having the anti-HBs titer were ≥ 100 mUI/ml,&#xD;
      poor responders having anti-HBs titer between 10 and 99 mUI/ml, and nonresponders having&#xD;
      anti-HBs titer &lt; 10 mIU/ml. The Seroprotection rate by age group in the healthy population is&#xD;
      100% in the 18-29-year-old group, 98.9% in the 30-29 %-year-old group, 97.2% in the&#xD;
      40-49-year-old group, 95.2% in the 50-59-year-old group, 91.6% in 60-70-year-old group.&#xD;
      However, 5% of the general population will not mount a protection response.&#xD;
&#xD;
      Response to HBV vaccine is variable among patients with chronic diseases, such as HIV&#xD;
      infection, celiac disease, IBD, end-stage renal disease, diabetes. The immunogenicity of the&#xD;
      hepatitis B vaccine is also lower in decompensated cirrhosis. Among cirrhotic patients, only&#xD;
      45% who received Heplisav-B achieved immunity in investigator's previous retrospective&#xD;
      analysis. The usual approach to HBV vaccine nonresponse is repeating the vaccine series in&#xD;
      noninfected individuals.&#xD;
&#xD;
      Investigational Plan&#xD;
&#xD;
      *Study Design &amp; Duration: Patients with cirrhosis or chronic liver disease presented to the&#xD;
      hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have&#xD;
      immunity against Hepatitis B (defined as anti-HBs titer &lt; 10 mIU/ml) will be recruited.&#xD;
      Patients will be stratified based on cirrhosis vs. no-cirrhosis and vaccine naive vs. vaccine&#xD;
      experienced. Patients who had more than one vaccination series will not be included. Previous&#xD;
      vaccination could be either Heplisav or Engerix; however, this information will be collected.&#xD;
      The investigators' plan is to do the 1st part of the study is in treatment-naive patients and&#xD;
      expand it to vaccine experienced.&#xD;
&#xD;
      Investigators will randomize patients to receive Heplisav-B in 0, 4 weeks, or Heplisav-B in&#xD;
      0, 4, 8 weeks. The HBV surface antibody titer will be checked 8 to 12 weeks after&#xD;
      administration of the vaccination series and classified into good responders, poor&#xD;
      responders, and nonresponders based on antibody titers.&#xD;
&#xD;
      Investigators will collect basic data including age, MELD scores, etiologies of cirrhosis&#xD;
      (non-alcoholic fatty liver disease, hepatitis C, alcohol-induced liver disease, autoimmune&#xD;
      liver disease, primary biliary cholangitis, primary sclerosing cholangitis, others),&#xD;
      comorbidities (chronic obstructive pulmonary disease, diabetes mellitus, hypertension,&#xD;
      coronary artery disease, renal failure, obesity), immunosuppressive drugs.&#xD;
&#xD;
      Primary endpoint: Seroconversion or immunity is defined as HBsAb level ≥ 10 mIU/ml.&#xD;
&#xD;
      Randomization process:&#xD;
&#xD;
      Investigators will use the envelope allocation technique. At first, Investigators will create&#xD;
      a sequentially numbered random group assignment. The supplies for the randomization envelopes&#xD;
      include envelopes, back carbon paper, and white copy paper. On the white copy paper,&#xD;
      Investigators will write the study ID. Investigators will wrap the white copy paper inside&#xD;
      the black carbon paper, put those into the envelope, and seal it.&#xD;
&#xD;
      The above data will be prospectively collected and entered into an excel database in a&#xD;
      de-identified mode by giving them a coded number. Investigators will save data in a&#xD;
      password-protected format and filed in the GI Research share drive and only the study staff&#xD;
      will have access to the file to download for any study procedure or audit. It will be stored&#xD;
      in a confidential manner, indefinitely in a secured Mercy share drive according to the 21 CFR&#xD;
      part 11 guidelines.&#xD;
&#xD;
      The sample size for both arms: total 200. The current seroconversion rate of the hepatitis B&#xD;
      vaccine in cirrhosis is low, about 50%, with the conventional schedule, either Engerix 0, 1&#xD;
      month, 6 months or Heplisav-B 0, 1 month. Investigators aim for the seroconversion rate of&#xD;
      70% with Heplisav-B 0, 1 month, 2 months. The probability of type I error is 5% and the power&#xD;
      is 80%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rates of seroconversion after two doses of Heplisav-B given at 0 and 4 weeks versus three doses of Heplisav-B given at 0, 4 weeks, and 8 weeks.</measure>
    <time_frame>12 weeks after completing Heplisav-B series with two doses or three doses</time_frame>
    <description>The rates of seroconversion is defined as an HBsAg antibody concentration ≥ 10 mIU/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors are associated with a lower likelihood of achieving immunogenicity, such as age, race, MELD scores, etiologies of cirrhosis, comorbidity, immunosuppressive drugs. Those information will be measured or described descriptively by chart review.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Age (years) Race (White, Black, Other). MELD (Model For End-Stage Liver Disease) score: 6-40&#xD;
Etiologies of cirrhosis will include:&#xD;
Nonalcoholic Fatty Liver Disease (Yes/No). Hepatitis C (Yes/No). Alcohol induced Liver Disease (Yes/No). Autoimmune Hepatitis (Yes/No). Primary Biliary Cholangitis (Yes/No). Primary Sclerosing Cholangitis (Yes/No).&#xD;
Comorbidity will include:&#xD;
Chronic obstructive pulmonary disease (Yes/No). Diabetes mellitus (Yes/No). Hypertension (Yes/No). Coronary artery disease (Yes/No). Acute renal injury (Yes/No). Chronic renal disease (Yes/No). Obesity (Yes/No). The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared. A BMI of 30 and higher is considered obese. Immunosuppressive drugs (Yes/No).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Cirrhosis, 3-dose regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis, 2-dose regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non cirrhosis, 3-dose regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non cirrhosis, 2-dose regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heplisav-B Injectable Product, 2-dose regimen</intervention_name>
    <description>Investigators will randomly assign patients into a 2-dose regimen.</description>
    <arm_group_label>Cirrhosis, 2-dose regimen</arm_group_label>
    <arm_group_label>Non cirrhosis, 2-dose regimen</arm_group_label>
    <other_name>2-dose regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heplisav-B Injectable Product, 3-dose regimen</intervention_name>
    <description>Investigators will randomly assign patients into a 3-dose regimen.</description>
    <arm_group_label>Cirrhosis, 3-dose regimen</arm_group_label>
    <arm_group_label>Non cirrhosis, 3-dose regimen</arm_group_label>
    <other_name>3-dose regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - All the cirrhosis patients more than 18 years old presented to the hepatology clinic in&#xD;
        Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis&#xD;
        B (defined as anti-HBs titer &lt; 10 mIU/ml) will be recruited.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B&#xD;
             vaccine, a component of the hepatitis B vaccine, or yeast should not receive the&#xD;
             hepatitis B vaccine.&#xD;
&#xD;
          -  Those who had previous exposure to hepatitis B.&#xD;
&#xD;
          -  Post liver transplant patients.&#xD;
&#xD;
          -  Less than 18 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Thuluvath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHAU TO, MD</last_name>
    <phone>(714)-400-1331</phone>
    <email>cto@mdmercy.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Thuluvath, MD</last_name>
    <phone>(410)-332-9308</phone>
    <email>pthuluv@mdmercy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHAU TO, MD</last_name>
      <phone>714-400-1331</phone>
      <email>cto@mdmercy.com</email>
    </contact>
    <contact_backup>
      <last_name>PAUL THULUVATH, MD</last_name>
      <phone>(410)-332-9308</phone>
      <email>pthuluv@mdmercy.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview</url>
    <description>CDC. Overview and statistics of Hepatitis B.</description>
  </link>
  <results_reference>
    <citation>A two-dose hepatitis B vaccine for adults (Heplisav-B). Med Lett Drugs Ther. 2018 Jan 29;60(1539):17-18. Corrected and republished in: JAMA. 2018 Feb 27;319(8):822-823.</citation>
    <PMID>29364196</PMID>
  </results_reference>
  <results_reference>
    <citation>Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013:196704. doi: 10.1155/2013/196704. Epub 2013 Jun 6.</citation>
    <PMID>23840211</PMID>
  </results_reference>
  <results_reference>
    <citation>Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS; HBV-23 Study Group. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27.</citation>
    <PMID>29289383</PMID>
  </results_reference>
  <results_reference>
    <citation>Yanny B, Konyn P, Najarian LM, Mitry A, Saab S. Management Approaches to Hepatitis B Virus Vaccination Nonresponse. Gastroenterol Hepatol (N Y). 2019 Feb;15(2):93-99.</citation>
    <PMID>31011303</PMID>
  </results_reference>
  <results_reference>
    <citation>Shetty A, Jun Yum J, Saab S. The Gastroenterologist's Guide to Preventive Management of Compensated Cirrhosis. Gastroenterol Hepatol (N Y). 2019 Aug;15(8):423-430.</citation>
    <PMID>31592079</PMID>
  </results_reference>
  <results_reference>
    <citation>Amjad W, Alukal J, Zhang T, Maheshwari A, Thuluvath PJ. Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease. Dig Dis Sci. 2021 Jun;66(6):2101-2106. doi: 10.1007/s10620-020-06437-6. Epub 2020 Jul 2.</citation>
    <PMID>32617767</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Medical Center</investigator_affiliation>
    <investigator_full_name>Paul Thuluvath, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hepatitis B vaccine</keyword>
  <keyword>Heplisav-B</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>chronic liver disease</keyword>
  <keyword>2 dose regimen</keyword>
  <keyword>3 dose regimen</keyword>
  <keyword>non responder</keyword>
  <keyword>poor responder</keyword>
  <keyword>no response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT04588077/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT04588077/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

